Regenxbio Inc

NASDAQ:RGNX

35.15

-0.03 (-0.08%)

Market Cap (Intraday)	1.49B
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$18.59 Million
Adjusted EPS	-$1.24

See more estimates

10-Day MA	N/A
50-Day MA	N/A
200-Day MA	N/A

See more pivots

REGENXBIO, Inc. Stock, NASDAQ:RGNX

9600 Blackwell Road, Suite 210, Rockville, Maryland 20850

United States of America

Phone: +1.240.552.8181

Number of Employees: 257

http://www.regenxbio.com

Description

REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.